Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of January 25th – 31st, 2021.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
While Most of Us Are Eager to Put 2020 Behind Us, a Few Industries Had Banner Years During the Lockdown
Pizza delivery and Zoom subscriptions may top the list but it was also a huge year for Psychedelics. From major legislative victories to a record number of companies going public to big-name celeb endorsements, 2020 was, to say the least, one heck of a trip. The momentum is snowballing, and 2021 will be even bigger and better for Psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.
Shawn “Jay-Z” Carter’s Cannabis Brand is Now Public
The Parent Company GRAMF, a vertically integrated cannabis operator focused on the California market, completed its merger with Subversive Capital Acquisition Corp. SBVCF in mid-January. The $1.2 billion deal is the largest Cannabis deal ever involving a Special Purpose Acquisition Company and makes The Parent Company the largest vertically integrated operator in the state. According to Jay-Z, the goal is not to just become the largest player in the largest cannabis market—California represents 22% of the U.S. legal cannabis market opportunity—but to empower minority-owned cannabis businesses as well.
Lawmakers in Connecticut and Florida Have Filed New Bills to Reform State Laws on Psilocybin Mushrooms—the Latest in a Trend of Psychedelics Proposals to Emerge in 2021
Rep. Michael Grieco (D) filed the Florida legislation on Thursday, which would establish a legal Psilocybin model for therapeutic use in the state, similar to an initiative that Oregon voters approved in November. It also seeks to deprioritize criminal enforcement against a wide range of Psychedelic plants and fungi.
RWB’s Second High Times Release Will Be Available in Twice the Number of Dispensaries as the December Launch and Feature Three New Unique Strains:
Red White & Bloom RWBYF announced on Wednesday, the second release of its exclusive line of High Times branded cannabis products in Michigan. The company’s quick follow-up release is in response to soaring cannabis demand in Michigan after last month’s initial launch sold out in just hours.
Cannabis Companies in Arizona’s Fledgling Recreational Market Are Reporting Long Lines and Robust Sales After a Lightning-Quick Market Launch Less Than 3 Months After Voters Approved Adult-Use Legalization
Seventy-three of the state’s 130 licenses were first approved for recreational sales on Jan. 22, and that total increased to 95 licenses approved by Wednesday. It’s being projected that Arizona’s recreational market could be worth $375 million-$400 million in Year One and $700 million-$760 million by 2024.
ATAI Life Sciences Announced on Tuesday a New Research Collaboration with Massachusetts General Hospital, the Largest Teaching Hospital of Harvard Medical School
The partnership will help advance the hospital’s Center for Neuroscience of Psychedelics, a recently-launched center focused on studying the mechanisms behind the therapeutic effects of Psychedelics, with the aims of developing novel mental health treatments. “This collaboration may lead to the discovery of novel mechanisms of neuroplasticity and development of more targeted treatments for mental illnesses, thereby pioneering the new frontier of precision mental health,” said ATAI Life Sciences Co-Founder and CSO Srinivas Rao.
Senate Majority Leader Chuck Schumer (D-NY) Says Lawmakers Are in the Process of Merging Various Marijuana Bills, Including His Own Legalization Legislation, as the Chamber Works to Enact Reform This Session
In an interview on Wednesday night with former NBA player Al Harrington, who owns the Cannabis company Viola Brands, Schumer talked about his support for ending federal cannabis prohibition, what he hopes reform to accomplish and the political state of play for Marijuana in the early days of the 117th Congress.
Today, Medical Professionals Are Researching the Benefits of Psychedelic Drugs and Perhaps Loosening Their Close Association in the Public’s Mind With 1960s Hippies and Rock Bands
As a half-century-long war on drugs winds down, it’s worth looking back on a long and tangled trail of contraband drugs and medical pharmaceuticals ranging from Bayer BAYRY trademarking heroin in 1895 to the legal prescription of medical marijuana in this century.
The Canadian Cannabis LP Index Started 2021 Strongly, Advancing 26.7% to 348.75
The Canadian Cannabis LP Index, which is rebalanced monthly, included 34 qualifying publicly-traded licensed producers that traded in Canada at the end of December, with equal weighting for each stock. Each of the members was also included in a sub-index, with 4 in the Canadian Cannabis LP Tier 1 Index, 11 in the Canadian Cannabis LP Tier 2 Index and 19 in the Canadian Cannabis LP Tier 3 Index during the month Canadian Licensed Producers (LPs) in Tier 1 include Aphria APHA, Aurora Cannabis ACB, Canopy Growth CGC and HEXO Corp HEXO.
Dr. Hyder Khoja is Hoping to Treat Coma Patients With Psychedelics in Order to “Jump-Start” Them Back Into Consciousness
The monumental potential that Psychedelics have to treat a panoply of psychopathologies is continuing to grow. At the time of writing, there are 59 clinical studies registered from all over the world that plan to use Psilocybin to treat mental health issues. That’s just one psychedelic out of a number being studied. But while many of these clinical trials are focusing on mental disorders like depression, anxiety, and OCD, Dr. Hyder Khoja (who sits on the Psychedelic Spotlight advisory board) aims to use these powerful compounds for something completely different. He argues that psychedelics can be used to re-ignite consciousness in unresponsive coma patients.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.